Rutgers University Receives 2017 Edison Patent Award For Polymer Used to Develop World’s First Fully Resorbable, X-Ray Visible Stent

Dr. Joachim Kohn’s “Biocompatible Polymers for Medical Devices” Invention Received Award from R&D Council of New Jersey in Biomaterials Category

Fantom(R) stent, REVA Medical Inc.

PISCATAWAY, NJ — A breakthrough patent – the polymer that enabled the development of the world’s first fully resorbable and x-ray visible coronary stent – invented by a Rutgers University researcher received the 2017 Edison Patent Award from the Research & Development Council of New Jersey. The award memorializes the state’s most prolific inventor, Thomas Alva Edison, and highlights the Garden State’s continuous pipeline of exceptional innovation work. 

The drug-eluting scaffold, or stent, is made from a unique formulation from a tyrosine-based polymer family invented by Dr. Joachim Kohn, Rutgers University-New Brunswick Board of Governors Professor in the Chemistry and Chemical Biology department at the School of Arts and Sciences, and director of the New Jersey Center for Biomaterials. The patent receiving the Edison Patent Award, “Biocompatible Polymers for Medical Devices” (U.S. Patent 8,252,887), provides the materials foundation for the development of the device, called the Fantom® stent, by REVA Medical Inc., a coronary stent company in San Diego, California dedicated to developing minimally-invasive medical devices.

“I am honored to receive the prestigious Edison Patent Award, but the true achievement is in the visibility and recognition that this award brings to the importance and value of research commercialization to society,” said Dr. Kohn. “When academia and industry partner together, there are no bounds to the innovation that can ensue. This invention will improve lives for people in New Jersey, across the nation, and around the world.”

According to the latest data available by Centers for Disease Control and Prevention (CDC), the number of adults in the U.S. with diagnosed heart disease in 2015 was 28.4 million. Coronary stents are one of the most widely used medical implants, and serve to keep the blood vessel open after angioplasty. Currently, most stents are made of metal and are easily detectable by x-ray imaging, which is critical to enable clinicians to see the position of the stent within the body of a patient.

Most recent clinical studies have shown that the danger of blood vessel closure, or re-stenosis, diminishes over time and in principle, after several months, the stent is no longer needed. Furthermore, the permanent presence of a non-degradable metal stent can become a significant long-term risk factor for the patient. These bioresorbable scaffolds are designed to provide all the proven benefits of commercial metal stents, but have the advantage of resorbing over time after the artery has stabilized and healed.

The Fantom® stent recently received the CE Mark, allowing it to be marketed and sold in Europe and other countries that recognize the Mark.

Rutgers University is among 14 winners of the 2017 Edison Patent Awards. Dr. Kohn, along with his co-inventors Durgadas Bolikal, Don K. Brandom, Lioubov Kabalnova, and Ernest G. Baluca, accepted the award at the 38th Edison Patent Awards Ceremony held at Liberty Science Center in Jersey City on November 2, 2017.

The awards for innovative patent work spanned 13 R&D categories, including: biomaterials, biomedical, energy, environmental, imaging systems, industrial process, information technology, instrumentation, materials, medical, pharmaceutical, technology transfer and telecommunications. Recipients of the 2017 Edison Patent Awards included: Avaya, BASF, Ethicon, ExxonMobil, Honeywell, Lexicon Pharmaceuticals, Merck, NJIT, Nokia Bell Labs, Princeton Plasma Physics Laboratory, Princeton University, Siemens, and Stevens Institute of Technology.

Following a call for nominations, the R&D Council assembles a committee of top state researchers across STEM (science, technology, engineering and math) disciplines who review the nominations and judge them based on four criteria: the significance of the problem researched, novelty and utility of the patent, and the patent’s commercial impact. Those with the highest scores are declared winners and join the ranks of the hundreds of researchers who are Edison Patent Award alumni. 

View tribute film about the Rutgers patent and inventor receiving the 2017 Edison Patent Award:  http://go.rutgers.edu/pisp17yi

# # #

About Rutgers, The State University of New Jersey

Rutgers, The State University of New Jersey, is a leading national research university and the state of New Jersey’s preeminent, comprehensive public institution of higher education. Established in 1766, the university is the eighth oldest higher education institution in the United States. Nearly 69,000 students and 22,000 full- and part-time faculty and staff learn, work, and serve the public at Rutgers locations across New Jersey and around the world. The university belongs to the Big Ten Academic Alliance, comprised of 14 world-class research universities, and is among the top 20 public U.S. universities for total R&D funding. Rutgers University–New Brunswick is the state’s only public institution in the prestigious Association of American Universities.

As the premier public research university in the state, Rutgers is dedicated to teaching that meets the highest standards of excellence, to conducting cutting-edge research that breaks new ground and aids the state’s economy, businesses, and industries, and to providing services, solutions, and clinical care that help individuals and the local, national, and global communities where they live. ored.rutgers.edu

About REVA

Medical REVA Medical is a medical device company focused on the development and commercialization of bioresorbable polymer technologies for vascular applications. The Company’s lead product, the Fantom® bioresorbable scaffold, received European CE Mark on April 3, 2017 for the treatment of coronary artery disease. REVA is located in San Diego, California, USA and employs over 50 people in the United States and Europe.

About the Research & Development Council of New Jersey

As the Research & Development Council of New Jersey, we collaborate among industry, academia and government to grow and strengthen STEM in education, innovation and the economy. The R&D Council is a nonprofit 501(c)(3) organization whose membership includes representatives from academia, government and industry, including several Fortune 500 companies. More information can be found at the R&D Council’s website: www.rdnj.org.